vs
BlackSky Technology Inc.（BKSY）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
BlackSky Technology Inc.的季度营收约是REGENXBIO Inc.的1.2倍（$35.2M vs $30.3M），BlackSky Technology Inc.净利率更高（-2.5% vs -221.3%，领先218.9%），REGENXBIO Inc.同比增速更快（43.0% vs 15.9%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 20.5%）
BlackSky Technology Inc.是一家领先的地理空间情报服务商，运营高重访率小型地球观测卫星星座，为全球政府、国防、关键基础设施及商业客户提供实时卫星影像、高级数据分析与动态监测解决方案，助力各类场景下的运营决策。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BKSY vs RGNX — 直观对比
营收规模更大
BKSY
是对方的1.2倍
$30.3M
营收增速更快
RGNX
高出27.1%
15.9%
净利率更高
BKSY
高出218.9%
-221.3%
两年增速更快
RGNX
近两年复合增速
20.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $35.2M | $30.3M |
| 净利润 | $-868.0K | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -11.8% | -190.0% |
| 净利率 | -2.5% | -221.3% |
| 营收同比 | 15.9% | 43.0% |
| 净利润同比 | 95.5% | -31.2% |
| 每股收益（稀释后） | $0.04 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BKSYRGNX
| Q4 25 | $35.2M | $30.3M | ||
| Q3 25 | $19.6M | $29.7M | ||
| Q2 25 | $22.2M | $21.4M | ||
| Q1 25 | $29.5M | $89.0M | ||
| Q4 24 | $30.4M | $21.2M | ||
| Q3 24 | $22.5M | $24.2M | ||
| Q2 24 | $24.9M | $22.3M | ||
| Q1 24 | $24.2M | $15.6M |
净利润BKSYRGNX
| Q4 25 | $-868.0K | $-67.1M | ||
| Q3 25 | $-15.3M | $-61.9M | ||
| Q2 25 | $-41.2M | $-70.9M | ||
| Q1 25 | $-12.8M | $6.1M | ||
| Q4 24 | $-19.4M | $-51.2M | ||
| Q3 24 | $-12.6M | $-59.6M | ||
| Q2 24 | $-9.4M | $-53.0M | ||
| Q1 24 | $-15.8M | $-63.3M |
毛利率BKSYRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率BKSYRGNX
| Q4 25 | -11.8% | -190.0% | ||
| Q3 25 | -85.8% | -176.3% | ||
| Q2 25 | -62.8% | -296.3% | ||
| Q1 25 | -40.5% | 13.6% | ||
| Q4 24 | -20.0% | -242.1% | ||
| Q3 24 | -58.7% | -256.6% | ||
| Q2 24 | -47.0% | -251.3% | ||
| Q1 24 | -54.7% | -408.8% |
净利率BKSYRGNX
| Q4 25 | -2.5% | -221.3% | ||
| Q3 25 | -78.2% | -208.3% | ||
| Q2 25 | -185.8% | -331.8% | ||
| Q1 25 | -43.4% | 6.8% | ||
| Q4 24 | -63.9% | -241.3% | ||
| Q3 24 | -55.8% | -246.3% | ||
| Q2 24 | -37.7% | -237.7% | ||
| Q1 24 | -65.2% | -405.4% |
每股收益（稀释后）BKSYRGNX
| Q4 25 | $0.04 | $-1.30 | ||
| Q3 25 | $-0.44 | $-1.20 | ||
| Q2 25 | $-1.27 | $-1.38 | ||
| Q1 25 | $-0.42 | $0.12 | ||
| Q4 24 | $-0.61 | $-0.99 | ||
| Q3 24 | $-0.66 | $-1.17 | ||
| Q2 24 | $-0.52 | $-1.05 | ||
| Q1 24 | $-0.88 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $124.5M | $230.1M |
| 总债务越低越好 | $201.1M | — |
| 股东权益账面价值 | $94.9M | $102.7M |
| 总资产 | $386.2M | $453.0M |
| 负债/权益比越低杠杆越低 | 2.12× | — |
8季度趋势，按日历期对齐
现金及短期投资BKSYRGNX
| Q4 25 | $124.5M | $230.1M | ||
| Q3 25 | $146.5M | $274.2M | ||
| Q2 25 | $93.8M | $323.3M | ||
| Q1 25 | $75.8M | $267.9M | ||
| Q4 24 | $52.5M | $234.7M | ||
| Q3 24 | $63.2M | $255.5M | ||
| Q2 24 | $41.2M | $290.4M | ||
| Q1 24 | $35.4M | $338.7M |
总债务BKSYRGNX
| Q4 25 | $201.1M | — | ||
| Q3 25 | $195.1M | — | ||
| Q2 25 | $122.5M | — | ||
| Q1 25 | $115.3M | — | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $98.8M | — | ||
| Q2 24 | $108.6M | — | ||
| Q1 24 | $85.0M | — |
股东权益BKSYRGNX
| Q4 25 | $94.9M | $102.7M | ||
| Q3 25 | $91.1M | $161.5M | ||
| Q2 25 | $86.6M | $213.7M | ||
| Q1 25 | $88.8M | $274.2M | ||
| Q4 24 | $94.0M | $259.7M | ||
| Q3 24 | $110.3M | $301.4M | ||
| Q2 24 | $76.5M | $348.3M | ||
| Q1 24 | $81.7M | $390.7M |
总资产BKSYRGNX
| Q4 25 | $386.2M | $453.0M | ||
| Q3 25 | $380.9M | $525.2M | ||
| Q2 25 | $310.8M | $581.0M | ||
| Q1 25 | $284.9M | $490.9M | ||
| Q4 24 | $254.1M | $466.0M | ||
| Q3 24 | $245.5M | $519.1M | ||
| Q2 24 | $224.3M | $569.4M | ||
| Q1 24 | $210.1M | $629.2M |
负债/权益比BKSYRGNX
| Q4 25 | 2.12× | — | ||
| Q3 25 | 2.14× | — | ||
| Q2 25 | 1.41× | — | ||
| Q1 25 | 1.30× | — | ||
| Q4 24 | 1.15× | — | ||
| Q3 24 | 0.90× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | 1.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-9.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BKSYRGNX
| Q4 25 | $-9.3M | $-52.3M | ||
| Q3 25 | $-39.0M | $-56.0M | ||
| Q2 25 | $-7.3M | $-49.3M | ||
| Q1 25 | $27.2M | $33.6M | ||
| Q4 24 | $-1.8M | $-31.6M | ||
| Q3 24 | $1.0M | $-40.5M | ||
| Q2 24 | $-1.8M | $-45.5M | ||
| Q1 24 | $-3.8M | $-55.5M |
自由现金流BKSYRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率BKSYRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度BKSYRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率BKSYRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BKSY
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
